University College London Hospitals
London, United Kingdom
23 recruiting
Showing 1–20 of 23 trials
Recruiting
Phase 1
A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Mosunetuzumab or Glofitamab in Combination With CC-220 and/or CC-99282 in Participants With B-Cell Non-Hodgkin Lymphoma
Non-Hodgkin Lymphoma
Hoffmann-La Roche121 enrolled26 locationsNCT05169515
Recruiting
Phase 3
Study of TDXd, Chemotherapy, Pembrolizumab, and Trastuzumab in First-Line Metastatic HER2-Positive Gastric or Gastroesophageal Junction Cancer
Gastric CancerGastroesophageal-junction Cancer
Daiichi Sankyo726 enrolled250 locationsNCT06731478
Recruiting
Phase 1Phase 2
A Study of JNJ-90014496 in Participants With B-Cell Non-Hodgkin Lymphoma
Lymphoma, Non-HodgkinLymphoma, B-CellLymphoma, Large B-Cell, Diffuse
Janssen Research & Development, LLC439 enrolled31 locationsNCT05421663
Recruiting
Phase 2
A Study of JNJ-90301900 in Combination With Chemoradiation Followed by Consolidation Immunotherapy for Non-Small Cell Lung Cancer (NSCLC)
Carcinoma, Non-Small Cell Lung
Johnson & Johnson Enterprise Innovation Inc.130 enrolled36 locationsNCT06667908
Recruiting
Phase 1
A Study of JNJ-89853413 for Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Neoplasms
Leukemia, Myeloid, AcuteMyelodysplastic Neoplasms
Janssen Research & Development, LLC115 enrolled9 locationsNCT06618001
Recruiting
Phase 1Phase 2
A Study of Amivantamab Alone or in Addition to Other Treatment Agents in Participants With Head and Neck Cancer
Squamous Cell Carcinoma of Head and Neck
Janssen Research & Development, LLC287 enrolled55 locationsNCT06385080
Recruiting
Phase 1Phase 2
A Clinical Study to Test if an Investigational Treatment Called BNT326 is Safe and Potentially Beneficial When Used Alone or in Combination With Other Investigational Treatments Such as BNT327, for People With Advanced Malignant Tumors
Advanced Solid Tumor
BioNTech SE980 enrolled53 locationsNCT07070232
Recruiting
Phase 3
A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma
Multiple Myeloma
Janssen Research & Development, LLC1,590 enrolled261 locationsNCT05552222
Recruiting
Phase 3
A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence
Breast Cancer
Stemline Therapeutics, Inc.4,220 enrolled524 locationsNCT06492616
Recruiting
Phase 2
A Study to Evaluate Preventive Treatments for Talquetamab-related Oral Toxicity
Refractory Multiple MyelomaRelapse Multiple Myeloma
Janssen Research & Development, LLC130 enrolled38 locationsNCT06500884
Recruiting
Phase 2
A Study of Amivantamab in Participants With Advanced or Metastatic Solid Tumors Including Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer
Carcinoma, Non-Small Cell Lung
Janssen Research & Development, LLC520 enrolled110 locationsNCT05498428
Recruiting
Phase 2Phase 3
A Clinical Trial Investigating the Safety, Tolerability, and Therapeutic Effects of BNT113 in Combination With Pembrolizumab Versus Pembrolizumab Alone for Patients With a Form of Head and Neck Cancer Positive for Human Papilloma Virus 16 and Expressing the Protein PD-L1
Unresectable Head and Neck Squamous Cell CarcinomaMetastatic Head and Neck CancerRecurrent Head and Neck Cancer
BioNTech SE350 enrolled189 locationsNCT04534205
Recruiting
Phase 3
A Clinical Study of the Anti-cancer Effects of an Investigational Therapy or Chemotherapy in Patients With Recurring Uterine Cancer
Endometrial Cancer
BioNTech SE480 enrolled80 locationsNCT06340568
Recruiting
Phase 1Phase 2
A Phase 1/2 Study of Bleximenib in Participants With Acute Leukemia (cAMeLot-1)
Acute Lymphoblastic LeukemiaAcute Myeloid LeukemiaAcute Leukemias
Janssen Research & Development, LLC400 enrolled101 locationsNCT04811560
Recruiting
Phase 3
A Study of Pasritamig Versus Placebo in Late Line Metastatic Castration-resistant Prostate Cancer (mCRPC)
Metastatic Castration-resistant Prostate Neoplasms
Janssen Research & Development, LLC663 enrolled81 locationsNCT07164443
Recruiting
Phase 1
Anti-CCR9 CAR T Cells for T Cell Leukaemia/Lymphoma
T-cell Acute Lymphoblastic LeukemiaT-Cell Lymphoblastic Lymphoma
University College, London24 enrolled1 locationNCT07300683
Recruiting
Phase 1Phase 2
Study of REGN4018 (Ubamatamab) Administered Alone or in Combination With Cemiplimab in Adult Patients With Recurrent Ovarian Cancer or Other Recurrent Mucin-16 Expressing (MUC16+) Cancers
Endometrial CancerRecurrent Ovarian CancerLow Grade Serous Ovarian Cancer+3 more
Regeneron Pharmaceuticals890 enrolled51 locationsNCT03564340
Recruiting
Phase 1Phase 2
A Trial to Learn if Linvoseltamab is Safe and Works in Adults With Relapsed or Refractory Systemic Light Chain Amyloidosis (AL Amyloidosis)
Relapsed/Refractory Systemic Light Chain Amyloidosis
Regeneron Pharmaceuticals220 enrolled18 locationsNCT06292780
Recruiting
Phase 1
A Study to Assess THN391 in Subjects With Alzheimer's Disease
Alzheimer Disease, Early Onset
Therini Bio, Inc.15 enrolled4 locationsNCT06814730
Recruiting
Phase 1Phase 2
A Study to Assess the Safety and Anti-Tumor Activity of REGN7945 in Combination With Linvoseltamab in Adult Participants With Relapsed/Refractory Multiple Myeloma
Relapsed/Refractory Multiple Myeloma
Regeneron Pharmaceuticals186 enrolled7 locationsNCT06669247